GSK plcGSK
▲ ポジティブ資本関連度
GSK's $10.6 billion acquisition of Nuvalent is a major M&A deal that signals GSK's strategic growth.
銘柄への影響 7
Biotech & Genomic Medicine
GSK plc
Eli Lilly and CompanyLLY
▲ ポジティブ資本関連度
Eli Lilly's acquisition of 10 companies this year, led by a $7.8 billion deal for Centessa, signals aggressive M&A strategy and industry confidence.
Nuvalent IncNUVL
▲ ポジティブ資本関連度
GSK's $10.6 billion acquisition of Nuvalent is a major M&A event that validates Nuvalent's value.
Parabilis Medicines, Inc. Common StockPBLS
▲ ポジティブ資本関連度
Parabilis set a new biotech IPO record with a $670 million Nasdaq listing, indicating strong investor demand.
Kailera Therapeutics, Inc. Common StockKLRA
▲ ポジティブ資本関連度
Kailera raised $625 million in a large biotech IPO, signaling strong capital market access.
Health Care
Centessa Pharmaceuticals PLC ADRCNTA
▲ ポジティブ資本関連度
Eli Lilly's $7.8 billion acquisition of Centessa is a major M&A event that validates Centessa's value.
Organon & CoOGN
▲ ポジティブ資本関連度
Sun Pharma's $11.75 billion takeover of Organon is a significant M&A deal that boosts Organon's valuation.
テーマインパクト
カバレッジ外企業 1
Sun Pharmaceutical Industries Ltd非上場▲ ポジティブ
資本関連度
Sun Pharma's $11.75 billion acquisition of Organon is a major M&A deal, boosting its pipeline and scale.